Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurological Sciences
Erschienen in: Neurological Sciences 1/2014

01.05.2014 | Key Note Lecture

New treatments for headache

verfasst von: Sarah Vollbracht, Alan M. Rapoport

Erschienen in: Neurological Sciences | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Migraine and cluster headache are primary headache disorders commonly encountered in clinical practice. Despite the profound disability caused by these primary headache disorders, available acute and preventive treatment options are limited. Recent understanding of headache pathophysiology has led to the development of new drug formulations and novel drug targets that are extremely promising. This article will highlight several of the new treatments that are currently under investigation including novel delivery mechanisms of already existing medications, calcitonin gene-related peptide (CGRP) receptor antagonists, antibodies to CGRP and its receptor, serotonin receptor agonists, transient receptor potential vanilloid receptor modulators, orexin receptor antagonists, glial cell modulators, and neuromodulation. If data is supportive, these therapies will be welcome additions to the headache specialist’s armamentarium.
Literatur
1.
2.
Robbins MS, Lipton RB (2010) The epidemiology of primary headache disorders. Semin Neurol 30:107–119PubMedCrossRef
3.
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675PubMedCrossRef
4.
5.
Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW et al (2009) Needle-free subcutaneous sumatriptan (Sumavel(™) DosePro(™)): bioequivalence and ease of use. Headache 49:1435–1444PubMedCrossRef
6.
Rothrock JF, Cady RK, Aurora SK, Brandes JL, Meyers JA, Fox AW et al (2011) Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-related functionality, satisfaction, and confidence. Curr Med Res Opin 27:2185–2191PubMedCrossRef
7.
Cady RK, Aurora SK, Brandes JL, Rothrock JF, Myers JA, Fox AW et al (2011) Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 51:1202–1211PubMedCrossRef
8.
Landy SH, Tepper SJ, Wein T, Schweizer E, Ramos E (2013) An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Headache 53:118–125PubMedCrossRef
9.
Vikelis M, Mitsikostas D, Rapoport AM (2012) Sumatriptan transdermal iontophoretic patch (NP101—Zelrix(™)): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr Dis Treat 8:429–434PubMedCentralPubMedCrossRef
10.
Goldstein J, Smith TR, Pugach N, Griesser M, Sebree T, Pierce M (2012) A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 52:1402–1410PubMedCrossRef
11.
Siegel SJ, O’Neill CO, Dube LM, Kaldeway P, Morris R, Jackson D et al (2007) A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res 24:1919–1926PubMedCrossRef
12.
Pierce M, Marbury T, O’Neill C, Siegel S, Du W, Sebree T (2009) Zelrix(™): a novel transdermal formulation of sumatriptan. Headache 49:817–825PubMedCrossRef
13.
Smith TR, Goldstein J, Singer R, Pugach N, Silberstein S, Pierce MW (2012) Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache 52:612–624PubMedCrossRef
14.
Luthringer R, Djupesland PG, Sheldrake CD, Flint A, Boeijinga P, Danjou P et al (2009) Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol 61:1219–1228PubMedCrossRef
15.
Djupesland PG, Docekal P, Czech Migraine Investigators G (2010) Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30:933–942PubMed
16.
Tepper SJ (2013) Clinical implications for breath-powered powder sumatriptan intranasal treatment. Headache 53:1341–1349PubMedCrossRef
17.
18.
Diener H-C, Montagna P, Gàcs G, Lyczak P, Schumann G, Zoller B et al (2006) Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 26:537–547PubMedCrossRef
19.
Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN et al (2010) Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the international migraine pain assessment clinical trial (IMPACT). Cephalalgia 30(11):1336–1345PubMedCrossRef
20.
Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E (2010) A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract 54:281–286
21.
Silberstein S (2012) MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother 13:1961–1968PubMedCrossRef
22.
Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo(™)) Inhaler. Headache 48:355–367PubMedCrossRef
23.
Aurora SK, Rozen TD, Kori SH, Shrewsbury SB (2009) A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 49:826–837PubMedCrossRef
24.
Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M et al (2011) MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 51:507–517PubMedCrossRef
25.
Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55:19–26PubMedCrossRef
26.
Burstein R, Jakubowski M (2004) Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 55:27–36PubMedCrossRef
27.
Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT et al (2012) Efficacy and safety of MAP0004, orally inhaled DHE in treating migraine with and without allodynia. Headache 52:37–47PubMedCrossRef
28.
Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedCrossRef
29.
Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L (1999) Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76:176–183PubMedCrossRef
30.
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L (2010) Differential distribution of calcitonin gene related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169:683–696PubMedCrossRef
31.
Edvinsson L, Gulbenkian S, Barrosco CP, Cunha e Sa M, Polack JM, Mortensen A et al (1998) Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 19:1213–1225PubMedCrossRef
32.
Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181PubMedCentralPubMedCrossRef
33.
Goadsby PJ (2007) Recent advances in understanding migraine mechanisms, molecules, and therapeutics. Trends Mol Med 13:39–44PubMedCrossRef
34.
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRef
35.
Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMedCrossRef
36.
Hewitt DJ, Martin V, Lipton RB, Brandes J, Ceesay P, Gottwald R et al (2011) Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache 51:533–543PubMedCrossRef
37.
Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2123PubMedCrossRef
38.
Connor KM, Shapiro RE, Diener HC, Lucus S, Kost J, Fan X et al (2009) Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73:970–977PubMedCentralPubMedCrossRef
39.
Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R et al (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712–722PubMedCrossRef
40.
Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J et al (2012) Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache 52:224–235PubMedCrossRef
41.
van der Schueren BJ, Blanchard R, Murphy MG, Palcza J, De Lepeleire I, Van Hecken A et al (2010) The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol 71:708–717CrossRef
42.
Ho AP, Dahlof CG, Silberstein SD, Saper JR, Ashina M, Kost JT et al (2010) Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 30:1443–1457PubMedCrossRef
43.
Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H et al (2011) Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 51:73–84PubMedCrossRef
44.
Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD (2011) Antimigraine efficacy of telcagepant based on patient’s historical triptan response. Headache 51:64–72PubMedCrossRef
45.
Hoffmann J, Goadsby PJ (2012) New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol 14:50–59PubMedCrossRef
46.
Han TH, Blanchard RL, Palcza J, McCrea JB, Laethem T, Willson K et al (2010) Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol 50:1367–1376PubMedCrossRef
47.
Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine: results from a phase II study. Cephalalgia 31:573–584PubMedCrossRef
48.
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114–125PubMedCrossRef
49.
50.
51.
52.
A single-dose, placebo-controlled, ascending dose study to determine the safety, tolerability, and pharmacokinetics of ALD403, a humanized anti-calcitonin gene-related peptide monoclonal antibody administered by intravenous infusion and subcutaneous injection. NCT10579383. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01579383. Accessed 13 Feb 2014
53.
54.
Bigal ME, Escandon R, Bronson M, Walter S, Sudwoth M, Huggins JP, et al (2013) Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase I program. Cephalalgia [Epub ahead of print]
55.
56.
57.
58.
Bigal ME, Walter S, Rapoport AM (2013) Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 53:1230–1244PubMedCrossRef
59.
60.
61.
62.
63.
Neeb L, Meents J, Reuter U (2010) 5-HT-1F receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics 7:176–182PubMedCrossRef
64.
Nelson DL, Phebus LA, Johnson KW (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmitidan. Cephalalgia 30:1159–1169PubMedCrossRef
65.
Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauass M (2010) Acute treatment of migraine with the selective 5-HT-1F receptor agonist lasmitidan—a randomised proof-of-concept trial. Cephalalgia 30:1170–1178PubMedCrossRef
66.
Fakkila M, Diener HC, Geraud G, Laniz JM, Schoenen J, Pilgrim AJ (2010) Lasmitidan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine. J Headache Pain 11(Suppl 1):S43
67.
Jansen-Olesen I, Mortensen A, Edvinsson L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16:310–316PubMedCrossRef
68.
Rapoport AM (2012) The therapeutic future in headache. Neurol Sci 22(Suppl 1):S119–S125CrossRef
69.
Saper JR, Klapper J, Mathew NT, Rapoport A, Phillips SB, Bernstein JE (2002) Intranasal civamide for the treatment of episodic cluster headache. Arch Neurol 59:990–994PubMedCrossRef
70.
71.
Diamond S, Freitag F, Phillips SB, Bernstein JE, Saper JR (2000) Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 20:597–602PubMedCrossRef
72.
Bartsch T, Levy MJ, Knight YE, Goadsby PJ (2004) Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 109:367–378PubMedCrossRef
73.
Holland PR, Akerman S, Goadsby PJ (2006) Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 24:2825–2833PubMedCrossRef
74.
Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM et al (2012) Pharmacololgical characterization of MK-6096—a dual orexin receptor antagonist for insomnia. Neuropharmacology 62:978–987PubMedCrossRef
75.
76.
Hanani M (2005) Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain Res Rev 48:457–476PubMedCrossRef
77.
Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE et al (2007) Neuron–Glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47:1008–1023PubMedCentralPubMedCrossRef
78.
Capuano A, DeCorato A, Lisi L, Tringali G, Navarra P, Dello Russo C (2009) Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain 5:43–55PubMedCentralPubMedCrossRef
79.
Ledeboer A, Tongyao L, Ahumilla JA, Mahoney JH, Vijay S, Gross MI et al (2006) The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glio Biol 2:279–291CrossRef
80.
Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW (2007) Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 16:935–950PubMedCrossRef
81.
82.
83.
Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH et al (2010) Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomized, double-blind, parallel-group, sham-controlled trial. Lancet Neurl 9:373–380
84.
Clarke BM, Upton ARM, Kamath MV, Al-Harbi T, Castellasnos CM (2006) Transcranial magnetic stimulation for migraine: clinical effects. J Headache Pain 7:341–346PubMedCentralPubMedCrossRef
85.
Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS (2007) Occipital nerve stimulation for chronic headache—long-term safety and efficacy. Cephalalgia 27:153–157PubMedCrossRef
86.
Matharu MS, Bartsch T, Ward N, Frackowiak RSJ, Weiner R, Goadsby PJ (2004) Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127:220–230PubMedCrossRef
87.
Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31:271–285PubMedCentralPubMedCrossRef
88.
Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A et al (2012) Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 32:1165–1179PubMedCrossRef
89.
Reed KL, Black SB, Banta CJ II, Will KR (2010) Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 30:260–271PubMed
90.
Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM et al (2013) Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia 33:816–830PubMedCentralPubMedCrossRef
91.
Sadler RM, Purdy RA, Rahey S (2002) Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia 22:482–484PubMedCrossRef
92.
Mauskop A (2005) Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia 25:82–86PubMedCrossRef
93.
Hord ED, Evans MS, Mueed S, Adamolekun B, Naritoku DK (2003) The effect of vagus nerve stimulation on migraines. J Pain 4:530–534PubMedCrossRef
94.
Lenaerts ME, Oommen KJ, Couch JR, Skaggs V (2008) Can vagus nerve stimulation help migraine? Cephalalgia 28:392–395PubMedCrossRef
95.
Cecchini AP, Mea E, Tullo V, Curone M, Franzoni A, Broggi G et al (2009) Vagus nerve stimulation in drug-resistant daily chronic migraine with depression preliminary data. Neurol Sci 30:S101–S104PubMedCrossRef
96.
Oshinsky ML, Murphy AL, Cooper ME, Simon BJ (2013) Trigeminal pain is suppressed by non-invasive vagal nerve stimulation in a rat headache model. J Headache Pain 1:P80CrossRef
97.
Goadsby P (2013) Non-invasive vagus nerve stimulation (nVNS) for acute treatment of migraine: an open-label pilot study. In: American Academy of Neurology’s 65th AAN Annual Meeting. San Diego, CA, USA
98.
Nesbitt AD, Marin JCA, Tomkins E, Ruttledge MH, Goadsby PJ (2013) Non-invasive vagus nerve stimulation for the treatment of cluster headache: a case series. J Headache Pain 1:P231CrossRef
99.
Gerardy PY, Fabry D, Fumal A, Schoenen J (2009) A pilot study on supra-orbital surface electrotherapy in migraine. Cephalalgia 29:134
100.
Schoenen J, Vandermissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P et al (2013) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80:697–704PubMedCrossRef
101.
Magis D, Salva S, D’Elia TS, Baschi R, Schoenen J (2013) Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain 14:95PubMedCrossRef
102.
Metadaten
Titel
New treatments for headache
verfasst von
Sarah Vollbracht
Alan M. Rapoport
Publikationsdatum
01.05.2014
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe Sonderheft 1/2014
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-014-1747-z

Weitere Artikel der Sonderheft 1/2014

Neurological Sciences 1/2014 Zur Ausgabe

SESSION IV UNCONVENTIONAL TREATMENTS

Riboflavin and migraine: the bridge over troubled mitochondria

FICEF SYMPOSIUM - Headache in the front line: from pharmacist to general practitioner

Symptomatic treatment of migraine: from scientific evidence to patient management

SESSION I HEADACHE AT WORK AND AT SCHOOL

Headache in school age

SYMPOSIUM Botulinum toxin in clinical practice

Technique of injection of onabotulinumtoxin A for chronic migraine: the PREEMPT injection paradigm

ORAL COMMUNICATIONS

Sex-related differences in migraine

SESSION IV UNCONVENTIONAL TREATMENTS

Herbal therapy in migraine

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise